HIMS

We rate Hims & Hers Health, Inc. (HIMS) as Avoid with a composite score of 33.7/100 at a current price of $15.38. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.

The rating is primarily driven by strength in quality (50th percentile) and value (40th percentile), which together account for the majority of the composite score. Offsetting weakness in momentum (11th percentile) and stability (19th percentile) tempers our overall conviction. We assign a Narrow Moat rating (43/100), Very High uncertainty, and Poor capital allocation.

Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress; sustainability of the current growth rate. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.

Hims & Hers Health, Inc. holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 33.7/100 places it at rank #4242 in our full 7,333-stock universe. With a $12.8B market capitalization, Hims & Hers Health, Inc. operates at meaningful scale within the Services sector, providing competitive advantages in distribution, procurement, and customer reach.

Revenue is growing at 90%, though momentum at the 11th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.

The margin cascade tells an important story: gross margins of 76% (+16.1pp vs sector) narrow to operating margins of 6% (+2.1pp vs sector) and net margins of 9.4%, yielding a gross-to-net conversion rate of 12%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.

At a current price of $15.38, Hims & Hers Health, Inc. is trading at a premium to fundamental value. Our value factor score of 40/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.

The stock currently trades at a P/E of 19.4x (roughly in line with the sector median of 23.7x), EV/EBITDA of 29.9x (at a premium), P/B of 6.1x, P/S of 1.7x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.

We assign a Very High uncertainty rating to Hims & Hers Health, Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.97), significant leverage (284% debt-to-equity), below-average price stability (19th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.

Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.97); significant leverage (284% debt-to-equity); below-average price stability (19th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 19th percentile and quality factor at the 50th percentile provide a quantitative summary of the overall risk landscape.

Key risk mitigants include: healthy gross margins of 76% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.

We rate Hims & Hers Health, Inc.'s capital allocation as Poor. Key concerns include elevated leverage (284% D/E). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Hims & Hers Health, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.

Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.

In summary, Hims & Hers Health, Inc. receives a Avoid rating with a composite score of 33.7/100 (rank #4242 of 7,333). Our quantitative framework assigns a Narrow Moat (43/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 29/100.

Our analysis does not support a constructive view on Hims & Hers Health, Inc. at this time. The combination of the current quantitative profile, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.